NCT05615636 2026-03-16A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLM.D. Anderson Cancer CenterPhase 2 Recruiting36 enrolled